FBRX HealthcareBeta data

Forte Biosciences Inc

$76.99Unavailable

Price as of close on Aug 26, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.6B USD
Enterprise value: 1.7B USD
Full-time employees: 23

Overall health

Not enough data: too little is reported yet for an overall view

Only 2 of 4 categories have enough reported data; an overall score needs at least 3.

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Forte Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss over the last 12 months.
Forte Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
More volatile share price. Beta 2.65: tends to move more than the market.
Forte Biosciences's shares have swung more with the market than most peers' (beta 2.65, above the market's 1.0).

StockQuotient Score

—Fundamentals: Yahoo Finance, not primary filings

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-5.9%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-5.4%

Yahoo Finance · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-4.4%

Yahoo Finance · trailing 12 months · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield9.8%

Yahoo FinanceReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 0 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

2/3 inputs reported · Partial data

Why it changed since the Aug 26, 2026 close: Safety percentile 70 → 69

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.65

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio10.01×

Yahoo FinanceReported value33% base weight · Z-score 5.36Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Forte Biosciences

Is Forte Biosciences getting weaker?: Filing-by-filing changes are tracked only for companies that file with the US SEC.
How is Forte Biosciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.9% vs peers 1.5% (weaker than 100% of peers).
Is Forte Biosciences growing?: Insufficient data: 0 of 3 inputs reported (at least 2 needed).
How profitable is Forte Biosciences?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How risky is Forte Biosciences?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.01× vs a peer median of 2.59× (stronger than 87% of peers).Current ratio 10.01× vs peers 2.59× (stronger than 87% of peers). Beta 2.65 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.65 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Detailed annual statements come from structured SEC filing data, which most US companies and some foreign filers provide. They aren’t available for this company yet.

FBRX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Worth knowing

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Forte Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss over the last 12 months.

Forte Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

More volatile share price. Beta 2.65: tends to move more than the market.

Forte Biosciences's shares have swung more with the market than most peers' (beta 2.65, above the market's 1.0).

Questions investors ask about Forte Biosciences

Is Forte Biosciences getting weaker?

Filing-by-filing changes are tracked only for companies that file with the US SEC.

How is Forte Biosciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -5.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.9% vs peers 1.5% (weaker than 100% of peers).

Is Forte Biosciences growing?

Insufficient data: 0 of 3 inputs reported (at least 2 needed).

How profitable is Forte Biosciences?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How risky is Forte Biosciences?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.01× vs a peer median of 2.59× (stronger than 87% of peers).Current ratio 10.01× vs peers 2.59× (stronger than 87% of peers). Beta 2.65 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.65 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.